NCT00198159终止2 期
A Phase II Study of ZD1839 (Iressa)in Chemotherapy Refractory Germ Cell Tumors Expressing Epidermal Growth Factor Receptor (EGFR)
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 21
- 试验地点
- 2
- 主要终点
- To determine the response rate of ZD1839
研究概览
简要总结
This study will evaluate the use of ZD1839 in the treatment of subjects with refractory germ cell tumors. Subjects will take ZD1839 for one year in the absence of excessive toxicity or decision to withdraw.
详细描述
The primary objective is to determine the response rate of ZD1839 in patients with refractory germ cell tumors expressing EGFR. The secondary objectives are to determine the duration of response, time to progression and overall survival in patients with refractory germ cell tumors expressing EGFR and treated with ZD1839; to evaluate the tolerability of ZD1839 in patients with refractory germ cell tumors and to correlate tumor response to degree of EGFR expression by immunohistochemistry.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 15 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologic or serologic proof of metastatic germ cell neoplasm(gonadal or extragonadal primary) with disease not amenable to cure with either surgery or chemotherapy. Patients w/ seminoma and non-seminoma are eligible, as are women w/ ovarian germ cell tumors.
- •Evidence of recurrent or metastatic carcinoma
- •Must have received initial cisplatin combination therapy & demonstrated progression following the administration of at least one "salvage" regimen for advanced germ cell neoplasms.
- •Patients are eligible after first line platinum bsed chemotherapy if their disease has relapsed and they have primary mediastinal non seminomatous germ cell tumor, late relapse or progressed w/in 4 wks of last platinum dose.
- •immunohistochemical documentation of EGFR expression documented.
- •adequate organ function: ANC >/=150,plt >100K, total bili </= upper limit of normal(ULN). Pts w/ liver mets up to 3x ULN.Transaminases up to 1.5 x ULN if alk phos is </=ULN or alk phos may be up to 4x ULN if transaminases are </= ULN. Pts w/ liver mets may have alk phos up to 5x ULN. Serum crt </= 2.
- •ECOG performance status 0-2.
排除标准
- •Must be 3 weeks post major surgery, radiotherapy, or chemotherapy and hae recovered from all toxicity.
- •Active unresolved infection and/or are receiving concurrent treatment with parenteral antibiotics are ineligible.
- •Patients requiring steroids for symptomatic brain metastasis are not eligible.
- •Pregnant or lactating patients are not eligible.
- •Class III/IV heart disease
结局指标
主要结局
To determine the response rate of ZD1839
次要结局
- To determine duration of response, time to progression and overall survival
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
ZD 1839 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone TherapyProstate CancerNCT00025116NCIC Clinical Trials Group40
已完成
2 期
ZD 1839 in Treating Patients With Glioblastoma Multiforme in First RelapseBrain and Central Nervous System TumorsNCT00016991Duke University
已完成
2 期
ZD 1839 in Treating Patients With Metastatic or Recurrent Cancer of the Head and NeckHead and Neck CancerNCT00015964University of Chicago51
已完成
2 期
Phase II Iressa & Carbo/Gem in NSCLCCarcinoma, Non-Small-Cell LungNCT00264498AstraZeneca38
终止
1 期
Safety Trial of IRESSA, Cisplatin and Radiation Therapy for Patients With Head and Neck CancerHead and Neck CancerNCT00195078Weill Medical College of Cornell University29